论文信息 - Including pregnant and breastfeeding people in trials of novel LAED PrEP agents: perspectives from sub‐Saharan Africa community stakeholders - 字舞流文

Including pregnant and breastfeeding people in trials of novel LAED PrEP agents: perspectives from sub‐Saharan Africa community stakeholders

2022

S. Delany-Moretlwe | M. Hosseinipour | Rhonda R White | Molly C Dyer

[1] S. Delany-Moretlwe,et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis , 2022, The lancet. HIV.

[2] S. Delany-Moretlwe,et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial , 2022, The Lancet.

[3] T. Holtz,et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. , 2021, The New England journal of medicine.

[4] R. Shapiro,et al. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.